TCR² Therapeutics to Present at the Needham Healthcare Conference

Rhea-AI Summary

On April 8, 2021, TCR² Therapeutics (Nasdaq: TCRR) announced that CFO Ian Somaiya will present company progress at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:00 AM E.T. The presentation will be hosted on a virtual platform, with a live webcast available on the company's Investor page. TCR² focuses on developing novel T cell therapies for cancer patients, showcasing promising preclinical results with their TRuC^®-T cells. The company's lead candidates, gavo-cel and TC-110, are in Phase 1/2 trials for various cancers.

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, will present an update on Company progress at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021 at 8:00am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

When will TCRR present at the Needham Virtual Healthcare Conference?

TCR² Therapeutics (TCRR) will present on April 14, 2021, at 8:00 AM E.T.

Who will present for TCRR at the conference?

Ian Somaiya, the Chief Financial Officer, will present for TCR² Therapeutics.

Where can I watch the TCRR presentation?

The presentation can be viewed live on the Investor page of TCR² Therapeutics' website.

What are TCR²'s lead product candidates?

TCR²'s lead candidates are gavo-cel for solid tumors and TC-110 for hematological malignancies.

What type of therapies does TCRR develop?

TCR² develops novel T cell therapies for patients suffering from cancer.

What trials are TCRR's lead candidates currently in?

Gavo-cel and TC-110 are currently being studied in Phase 1/2 clinical trials.